ECSP22019360A - Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos - Google Patents

Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos

Info

Publication number
ECSP22019360A
ECSP22019360A ECSENADI202219360A ECDI202219360A ECSP22019360A EC SP22019360 A ECSP22019360 A EC SP22019360A EC SENADI202219360 A ECSENADI202219360 A EC SENADI202219360A EC DI202219360 A ECDI202219360 A EC DI202219360A EC SP22019360 A ECSP22019360 A EC SP22019360A
Authority
EC
Ecuador
Prior art keywords
nsd2
purinamines
piperidinil
inhibitors
methyl
Prior art date
Application number
ECSENADI202219360A
Other languages
English (en)
Spanish (es)
Inventor
Guoliang Xun
Counde Oyang
Ce Wang
Haibing Deng
Haiqiang Zeng
Jinbiao Liu
Qitao Xiao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP22019360A publication Critical patent/ECSP22019360A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ECSENADI202219360A 2019-08-14 2022-03-14 Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos ECSP22019360A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2019/100542 WO2021026803A1 (en) 2019-08-14 2019-08-14 Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
PCT/IB2020/057602 WO2021028854A1 (en) 2019-08-14 2020-08-12 Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents

Publications (1)

Publication Number Publication Date
ECSP22019360A true ECSP22019360A (es) 2022-04-29

Family

ID=72145436

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202219360A ECSP22019360A (es) 2019-08-14 2022-03-14 Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos

Country Status (20)

Country Link
US (3) US11420970B1 (enExample)
EP (2) EP4559915A1 (enExample)
JP (2) JP7638960B2 (enExample)
KR (1) KR102946008B1 (enExample)
CN (1) CN114585622B (enExample)
AU (1) AU2020328919A1 (enExample)
BR (1) BR112022002520A2 (enExample)
CO (1) CO2022002804A2 (enExample)
DK (1) DK4013755T3 (enExample)
EC (1) ECSP22019360A (enExample)
ES (1) ES3023540T3 (enExample)
FI (1) FI4013755T3 (enExample)
IL (2) IL289754B2 (enExample)
MX (1) MX2022001784A (enExample)
MY (1) MY209614A (enExample)
PH (1) PH12022550343A1 (enExample)
PL (1) PL4013755T3 (enExample)
PT (1) PT4013755T (enExample)
WO (2) WO2021026803A1 (enExample)
ZA (1) ZA202200519B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021026803A1 (en) * 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
ES2987269T3 (es) * 2019-09-20 2024-11-14 Novartis Ag Inhibidores de MLL1 y agentes anticancerígenos
KR20240158230A (ko) * 2022-01-05 2024-11-04 케이36 테라퓨틱스, 인크. 중수소-풍부 피페리디닐-메틸-퓨린 아민 및 관련 화합물 및 질환 및 병태 치료에 있어서 이것들의 용도
IL314895A (en) * 2022-02-16 2024-10-01 Duke Street Bio Ltd Pharmaceutical compound
IL316882A (en) * 2022-05-18 2025-01-01 K36 Therapeutics Inc Piperidinyl-methyl-purine amine D-tartaric acid salts, crystalline forms, and their use in the treatment of diseases and medical conditions
WO2023225150A1 (en) * 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225144A1 (en) * 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
US20250326752A1 (en) * 2022-05-18 2025-10-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023230026A1 (en) * 2022-05-23 2023-11-30 K36 Therapeutics, Inc. Piperidinyl-methylpurine benzenes and related compounds and their use in treating diseases and conditions
WO2023230038A1 (en) * 2022-05-23 2023-11-30 K36 Therapeutics, Inc. Piperidinyl-methylpurine pyrimidines and related compounds and their use in treating diseases and conditions
WO2024073282A2 (en) * 2022-09-26 2024-04-04 Board Of Regents, The University Of Texas System Heterocycles as modulators of nsd activity
WO2024073283A1 (en) * 2022-09-26 2024-04-04 Board Of Regents, The University Of Texas System Heterocycles as modulators of nsd activity
WO2024129670A1 (en) * 2022-12-12 2024-06-20 K36 Therapeutics, Inc. Pharmaceutical compositions containing a piperidinyl-methyl-purine amine and their use in treating diseases and conditions
US20250171445A1 (en) * 2023-11-17 2025-05-29 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
CN117720550A (zh) * 2023-12-14 2024-03-19 深圳市华先医药科技有限公司 (s)-3-甲基-4-氧代-2-氧杂-8-氮杂螺[4.5]癸烷-8-甲酸叔丁酯合成方法
CN117843641B (zh) * 2023-12-28 2025-04-25 和径医药科技（上海）有限公司 Nsd3抑制剂及其制备方法和应用
WO2025147514A1 (en) * 2024-01-02 2025-07-10 K36 Therapeutics, Inc. Piperidinyl-methyl-purineamine nsd2 inhibitor therapeutic methods and compositions for treating cancer
CN118459395A (zh) * 2024-05-10 2024-08-09 南通大学 一种5-(叔丁氧羰基氨基)哌啶-3-羧酸甲酯的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4331944B2 (ja) * 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
US7332486B2 (en) * 2002-08-08 2008-02-19 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
KR101111085B1 (ko) * 2002-09-27 2012-04-12 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규 아데닌 화합물 및 그 용도
JP2004137157A (ja) * 2002-10-16 2004-05-13 Sumitomo Pharmaceut Co Ltd 新規アデニン誘導体を有効成分として含有する医薬
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
MX2012004706A (es) * 2009-10-22 2012-06-08 Gilead Sciences Inc Derivados de purina o deazapurina utiles para el tratamiento de (inter alia) infecciones virales.
GB201204985D0 (en) 2012-03-21 2012-05-02 Genentech Inc Compounds
WO2019196918A1 (zh) 2018-04-13 2019-10-17 罗欣药业(上海)有限公司 五元杂环并嘧啶类化合物、药物组合物及用途
CN109223794B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物c6作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN108853110B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物a8作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
WO2021026803A1 (en) * 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
KR20240158230A (ko) 2022-01-05 2024-11-04 케이36 테라퓨틱스, 인크. 중수소-풍부 피페리디닐-메틸-퓨린 아민 및 관련 화합물 및 질환 및 병태 치료에 있어서 이것들의 용도
WO2023225150A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
IL316882A (en) 2022-05-18 2025-01-01 K36 Therapeutics Inc Piperidinyl-methyl-purine amine D-tartaric acid salts, crystalline forms, and their use in the treatment of diseases and medical conditions
WO2023225144A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
US20250326752A1 (en) 2022-05-18 2025-10-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions

Also Published As

Publication number Publication date
JP2025081505A (ja) 2025-05-27
CN114585622A (zh) 2022-06-03
IL289754B2 (en) 2025-09-01
CA3144542A1 (en) 2021-02-18
MX2022001784A (es) 2022-04-18
EP4013755B1 (en) 2025-01-08
EP4559915A1 (en) 2025-05-28
KR102946008B1 (ko) 2026-04-01
WO2021028854A1 (en) 2021-02-18
JP7638960B2 (ja) 2025-03-04
MY209614A (en) 2025-07-24
ZA202200519B (en) 2024-08-28
PL4013755T3 (pl) 2025-05-12
US11420970B1 (en) 2022-08-23
DK4013755T3 (da) 2025-03-31
PT4013755T (pt) 2025-05-02
CN114585622B (zh) 2024-08-09
ES3023540T3 (en) 2025-06-02
US20230002388A1 (en) 2023-01-05
IL289754B1 (en) 2025-05-01
IL320143A (en) 2025-06-01
IL289754A (en) 2022-03-01
CO2022002804A2 (es) 2022-04-08
EP4013755A1 (en) 2022-06-22
BR112022002520A2 (pt) 2022-05-10
PH12022550343A1 (en) 2023-03-13
US12312353B2 (en) 2025-05-27
US20250276971A1 (en) 2025-09-04
JP2022544946A (ja) 2022-10-24
FI4013755T3 (fi) 2025-04-02
WO2021026803A1 (en) 2021-02-18
KR20220047330A (ko) 2022-04-15
AU2020328919A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
CO2022002804A2 (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
CO2022010460A2 (es) Compuestos tricíclicos sustituidos
CL2019003086A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
CR20220312A (es) Compuestos tricíclicos sustituidos
MX2019010539A (es) Compuestos de imidazo-piperidina fusionada que contienen una amida heterociclica de 4 miembros como inhibidores de jak.
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CL2020000283A1 (es) Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak.
MX2018001193A (es) Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos.
CO2021002976A2 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
CL2020001244A1 (es) Inhibidores de inmunoproteasoma.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
UY37569A (es) Inhibidores del inmunoproteasoma
CL2022001317A1 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma.
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
PH12020551620A1 (en) Compositions for preventing or treating dry eye
PE20191745A1 (es) Compuestos de acido ascorbico y quinona para el tratamiento de la enfermedad de chagas
AR111416A2 (es) Compuesto terapéutico para el dolor y síntesis del compuesto